Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids

Centre Oscar Lambret100 enrolled

Overview

Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Breast Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged 18 years or more * Histologically confirmed breast cancer at any stage * Requiring surgery or tumor biopsy as standard of care * Any or no systemic treatment * Signed informaed consent * Health insurance coverage Exclusion Criteria: * Opposed to biospecimen collection

Locations (1)

Oscar Lambret Center

Lille, France

RECRUITING

Outcomes

Primary Outcomes

Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers

Measurement of the phagocytic capacity

Time frame: 24 months

Antitumor activity of the CAR-macrophages compared to non-modified macrophages

Measurement of the phagocytic capacity

Time frame: 24 months

Secondary Outcomes

Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients

Measurement of the phagocytic capacity

Time frame: 24 months

Central Contacts

Nawale HAJJAJI, MD PhD

CONTACT

+33 320295910 n-hajjaji@o-lambret.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.